Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Clin Cancer Res. 2011 Jan 25;17(3):483–493. doi: 10.1158/1078-0432.CCR-10-1670

Fig. 3.

Fig. 3

Combination of dasatinib, erlotinib and gemcitabine effectively inhibits tumor growth in vivo. Mice with subcutaneously established tumors from (A) BxPC3 (n=5) (B) or PANC1 (n=5) cells were treated with dasatinib (DTB) at 25 mg/kg daily and/or gemcitabine (GEM) at 20 mg/kg for every 3 days and/or erlotinib (ERL) at 50 mg/kg/daily or vehicle for 14 days. Growth curves for tumors are presented as the mean ± SD of five tumors in each data point.